HM74a agonists: Will they be the new generation of nicotinic acid?

Current Topics in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 428-435

  Martes, Paul ^a  

^a GLAXOSMITHKLINE   (France)

Author keywords

GPR109a; HDL cholesterol; HM74a; Nicotinic acid; PUMA G

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACIFRAN; ACIPIMOX; ANTHRANILIC ACID DERIVATIVE; ANTILIPEMIC AGENT; CHOLESTEROL; FATTY ACID; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LAROPIPRANT PLUS NICOTINIC ACID PLUS SIMVASTATIN; MK 0354; MK 0524 A; MK 0524 B; NICOTINAMIDE; NICOTINIC ACID; PLACEBO; PROTEIN HM74A; PROTEIN HM74A AGONIST; PYRANO[2,3 D]PYRIMIDINE DERIVATIVE; PYRANONE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDIN 4 ONE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HOT FLUSH; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; DRUG DESIGN; FLUSHING; HUMANS; MOLECULAR STRUCTURE; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66649106645     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788340814     Document Type: Review

References (60)

1. Elvehjem, C. A.; Madden, R. J.; Strong, F. M.; Woolley, D. W. The isolation and identification of the anti-blacktongue factor. J. Biol. Chem. 1938, 123, 137-149.
2. Holman, W.; De Lange, D.J. Significance of tryptophane in human nicotinic acid metabolism. Nature 1950, 165(4186), 112.
3. Altschul, R.; Hoffer, A.; Stephen, J. D. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys. 1955, 54, 558-559.
4. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J. Am. Medi. Assoc. 1975, 231, 360-81.
5. Guyton, J. R. Niacin in cardiovascular prevention: Mechanisms, efficacy, and safety. Curr. Opin. Lipid 2007, 18(4), 415-420.
6. Gille, A.; Bodor, E. T.; Ahmed, K.; Offermanns, S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 79-106
7. (a) Spies, T. D.; Cooper, C.; Blankenhorn, M. A. The use of nicotinic acid in the treatment of pellagra. J. Am. Med. Assoc. 1938, 110, 622-627.
8. (b) Goldsmith, G. A.; Cordill, S. The vasodilating effects of nicotinic acid. (Relation to metabolic rate and body temperature.). Am. J. Med. Sci. 1943, 205, 204-208.
9. (a) Butcher, R. W.; Baird, C. E.; Sutherland, E. W. Effects of lipolytic and antilipolytic substances on adenosine 3′,5′-monophosphate levels in isolated fat cells. J. Biol. Chem. 1968, 243(8), 1705-1712.
10. (b) Malik S.; Kashyap M. L. Niacin, lipids, and heart disease. Curr. Cardiol. Rep 2003, 5(6), 470-476.
11. Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.; Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA - G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 2003, 9(3), 352-355.
12. Wise, A.; Foord, S. M.; Fraser, N. J.; Barnes, A. A.; Elshourbagy, N.; Eilert, M.; Ignar, D. M.; Murdock, P. R.; Steplewski, K.; Green, A.; Brown, A. J.; Dowell, S. J.; Szekeres, P. G.; Hassall, D. G.; Marshall, F.H.; Wilson, S.; Pike, N. B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 2003, 278(11), 9869-9874.
13. Soga, T.; Kamohara, M.; Takasaki, J.; Matsumoto, S-I; Saito, T.; Ohishi, T.; Hiyama, H.; Matsuo, A.; Matsushime, H.; Furuichi, K. Molecular identification of nicotinic acid receptor. Biochem. Biophy. Res. Comm. 2003, 303(1), 364-369.
14. Taggart, A. K. P.; Kero, J.; Gan, X.; Cai, T.Q.; Cheng, K.; Ippolito, M.; Ren, N.; Kaplan, R.; Wu, K.; Wu, T-J.; Jin, L.; Liaw, C.; Chen, R.; Richman, J.; Connolly, D.; Offermanns, S.; Wright, S. D.; Waters, M. G. (D)-ß - Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 2005, 280(29), 26649-26652.
15. McCormack, P. L.; Keating, G. M. Prolonged - release nicotinic acid: A review of its use in the treatment of dyslipidaemia. Drugs 2005, 65(18), 2719-2740.
16. Pieper, J. A. Overview of niacin formulations: Differences in pharmacokinetics, efficacy, and safety. Am. J. Health-Syst. Pharm. 2003, 60(13, Suppl. 2), S9-S14
17. Pieper J. A. Understanding niacin formulations. Am. J. Manag. Care 2002, 8(12 Suppl), S308-14.
18. Cefali, E. A.; Simmons, P. D.; Stanek, E. J.; Shamp, T. R. Improved control of niacin - induced flushing using an optimized once-daily, extended-release niacin formulation. Int. J. Clin. Pharm. Ther. 2006, 44(12), 633-640.
19. Cefali, E. A.; Simmons, P. D.; Stanek, E. J.; McGovern, M. E.; Kissling, C. J. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int. J. Clin. Pharm. Ther. 2007, 45(2), 78-88.
20. Benyo, Z.; Gille, A.; Kero, J.; Csiky, M.; Suchankova, M. C.; Nuesing, R. M.; Moers, A.; Pfeffer, K.; Offermanns, S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Inves. 2005, 115(12), 3634-3640.
21. Benyo, Z.; Gille, A.; Bennett, C. L.; Clausen, B. E.; Offermanns, S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol. Pharm. 2006, 70(6), 1844-1849.
22. Cheng K.; Wu, Ti-J.; Wu, K. K.; Sturino, C., Metters, K,; Gottesdiener, K.; Wright, S. D.; Wang, Z.; O'Neill, G.; Lai, E.; Waters, M. G. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc, Natl. Acad. Sci. USA 2006, 103(17), 6682-6687.
23. Maciejewski-Lenoir, D.; Richman, J. G.; Hakak, Y.; Gaidarov, I; Behan, D. P.; Connolly, D. T. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest. Dermatology 2006, 126(12), 2637-2646.
24. Morrow, J. D.; Parsons, W. G. III.; Roberts, L. J., II. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38(2), 263-274.
25. Paolini, J. F.; Mitchel, Y. B.; Reyes, R.; Kher, U.; Lai, E.; Watson, D. J.; Norquist, J. M.; Meehan, A. G.; Bays, H.E.; Davidson, M.; Ballantyne, C.M. Effects of laropiprant on nicotinic acid -induced flushing in patients with dyslipidemia. Am. J. Cardio. 2008, 101(5), 625-630.
26. Lai, E.; De Lepeleire, I.; Crumley, T. M.; Liu, F.; Wenning, L. A.; Michiels, N.; Vets, E.; O'Neill, G.; Wagner, J. A.; Gottesdiener, K. Suppression of niacin - induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 2007, 81(6), 849-857.
27. Richman, J. G.; Kanemitsu-Parks, M.; Gaidarov, I.; Cameron, J.S.; Griffin, P.; Zheng, H.; Guerra, N. C.; Cham, L.; MaciejewskiLenoir, D.; Behan, D. P.; Boatman, D.; Chen, R.; Skinner, P.; Ornelas, P.; Waters, M. G.; Wright, S. D.; Semple, G.; Connolly, D. T. Nicotinic acid receptor agonists differentially activate downstream effectors. J. Biol. Chem. 2007, 282(25), 18028-18036.
28. Semple, Gr.; Skinner, J.; Gharbaoui, T.; Shin, Y-J.; Jung, J-K.; Cherrier, M. C.; Webb, P. J.; Tamura, S. Y.; Boatman, P. D.; Sage, C. R.; Schrader, T. O.; Chen, R.; Colletti, S. L.; Tata, J. R.; Waters, M. G.; Cheng, K.; Taggart, A. K.; Cai, T.; Carballo-Jane, E.; Behan, D. P.; Connolly, D. T.; Richman, J. G. 3-(1H-Tetrazol-5yl)- 1, 4, 5, 6-tetrahydro-cyclopentapyrazole (MK - 0354): A partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J. Med. Chem. 2008, 51(16), 5101-5108.
29. Ashwood, M. S.; Bio, M.; Cleator, E.; Hands, D.; Sheen, F. J.; Wilson, R. D. Process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles from tetrazolylcarbonylcyclopentanones and hydrazine. PCT Int. Appl. 2006, WO06114581.
30. Lai, E.; Paolini, J.F. A niacin receptor partial agonist, MK-0354, robustly reduces plasma free fatty acids and produces little flushing but fails to alter LDL-C, HDL-C, and triglycerides in humans. Posters presented at the American Heart Association Scientific Session Nov 2007, see http://www.cardiosource.com/images/Lai_Poster.pdf
31. Colletti, S. L.; Beresis, R. T.; Chen, W.; Tata, J. R.; Shen, H. C.; Marley, D. M.; Deng, Q.; Frie, J. L.; Ding, F-X. N-Acyl anthranilic acid and related compounds as niacin receptor agonists, and their preparation, pharmaceutical compositions and methods of treatment of dyslipidemias. PCT Int. Appl. 2006, WO06052555.
32. Colletti, S. L.; Tata, J. R.; Shen, H. C.; Ding, F-X.; Frie, J. L.; Imbriglio, J. E.; Chen, W. Preparation of biaryl compounds, particularly N-(biarylpropionyl)anthranilides, as niacin receptor agonists and pyridoindolizine derivatives as DP receptor antagonists, their pharmaceutical compositions and their combination useful for treating atherosclerosis and dyslipidemias. PCT Int. Appl. 2006, WO06057922.
33. Raghavan, S.; Colletti, S. L.; Ding, F-X.; Shen, H.; Tata, J. R.; Lins, A. R.; Smenton, A. L.; Chen, W.; Schmidt, D. R.; Tria, G. S. Preparation of 2-acylaminocycloalkenecarboxylic acids derivatives as niacin receptor agonists. U.S. Pat. Appl. 2006, US 2006293364.
34. Colletti, S. L.; Shen, H.; Tata, J. R.; Szymonifka, M. J. Preparation of piperazinecarboxamides, diazepanecarboxamides and their analogs as niacin receptor agonists for the treatment of atherosclerosis, dyslipidemia and diabetes. PCT Int. Appl. 2007, WO07027532.
35. Imbriglio, J.; Colletti, S. L.; Tata, J. R.; Beresis, R. T.; Marley, D.; Raghavan, S.; Schmidt, D. R.; Lins, A. R.; Smenton, A. L.; Chen, W.; Shen, H.; Ding, F-X.; Bodner, R. Preparation of (hetero) aryl amino acid amides as niacin receptor agonists for treatment of atherosclerosis, dyslipidemia, diabetes, and metabolic syndrome. PCT Int. Appl. 2007, WO07075749.
36. Raghavan, S.; Schmidt, D. R.; Colletti, S.L.; Smenton, A. L. Preparation of carboxamidocyclohexenylcarboxylic acids derivatives as niacin receptor agonists, compositions containing such compounds and methods of treatment. PCT Int. Appl. 2007, WO07092364.
37. Dehmlow, H.; Grether, U.; Kratochwil, N. A.; Narquizian, R.; Panousis, C.; Peters, J-U. Preparation of benzoylanthranilic acid derivatives as G protein-coupled receptor HM74A agonists. U.S. Pat. Appl. Publ. 2006, US 2006281810.
38. Dehmlow, H.; Grether, U.; Kratochwil, N. A.; Narquizian, R.; Panousis, C. Preparation of acylaminothiophenecarboxylates as HM74A agonists. U.S. Pat. Appl. Publ. 2007, US 2007072873.
39. Campbell, M.; Hatley, R. J.; Heer, J. P.; Mason, A. M.; Pinto, I. L.; Rahman, S. S.; Smith, I. E. D. Preparation of anthranilic acid derivatives as selective agonists of the nicotinic acid receptor HM74A. PCT Int. Appl. 2005, WO05016867.
40. Campbell, M.; Hatley, R. J.; Heer, J. P.; Mason, A. M.; Nicholson, N. H.; Pinto, I. L.; Rahman, S. S.; Smith, I. E. D. Preparation of anthranilic acid derivatives as selective agonists of the nicotinic acid receptor HM74A. PCT Int. Appl. 2005, WO05016870.
41. Pinto, I. L.; Simpson, J. K. Preparation of heteroaryl carboxylic acid derivatives for treatment of diseases characterized by under activation of HM74A receptor. PCT Int. Appl. 2006, WO06085113.
42. Mason, A. M.; Pinto, Ivan Leo; Rahman, S. S. Preparation of anthranilic acid derivatives treating diseases active at the hm74a receptor. PCT Int. Appl. 2006, WO06085111.
43. Campbell, M.; Mason, A. M.; Pinto, I. L.; Pollard, D. R.; Smith, I. E. D. Preparation of anthranilic acid derivatives treating diseases active at the HM74A receptor and lipid metab. disorders. PCT Int. Appl. 2006, WO06085108.
44. Hatley, R.; Mason, A. M.; Pinto, I. L.; Smith, I.E. D. Preparation of anthranilic acid derivatives treating diseases active at the HM74A receptor. PCT Int. Appl. 2006, WO06085112.
45. Cao, G.; Xue, C-B.; Anand, R.; Huang, T.; Kong, L.; Glenn, J.; Feng, H. Preparation of disubstituted thienyl compounds as HM74a receptor modulators. PCT Int. Appl. 2007, WO07015744.
46. Shen, H. C.; Szymonifka, M. J.; Kharbanda, D.; Deng, Q.; Carballo-Jane, E.; Wu, K. K.; Wu, T-J.; Cheng, K.; Ren, N.; Cai, T-Q.; Taggart, A. K.; Wang, J.; Tong, X.; Waters, M. G.; Hammond, M. L.; Tata, J. R.; Colletti, S. L. Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A. Bioorg. Med. Chem. Lett. 2007, 17(24), 6723-6728.
47. Shen, H. C.; Ding, F-X.; Luell, S.; Forrest, M. J.; Carballo-Jane, E.; Wu, K. K.; Wu, T-J.; Cheng, K.; Wilsie, L. C.; Krsmanovic, M. L.; Taggart, A. K.; Ren, N.; Cai, T-Q.; Deng, Q.; Chen, Q.; Wang, J.; Wolff, M. S.; Tong, X.; Holt, T. G.; Waters, M. G.; Hammond, M. L.; Tata, J. R.; Colletti, S. L. Discovery of biaryl Anthranilides as full agonists for the high affinity niacin rceptor. J. Med. Chem. 2007, 50(25), 6303-6306.
48. Raghavan, S.; Tria, G. S.; Shen, H. C.; Ding, F-X.; Taggart, A. K.; Ren, N.; Wilsie, L. C.; Krsmanovic, M. L.; Holt, T. G.; Wolff, M. S.; Waters, M. G.; Hammond, M. L.; Tata, J. R.; Colletti, S. L. Tetrahydro anthranilic acid as a surrogate for anthranilic acid: Application to the discovery of potent niacin receptor agonists. Bioorg. Med. Chem. Lett. 2008, 18(11), 3163-3167.
49. Beresis, R. T.; Colletti, S. L. Preparation of indazole compounds as niacin receptor agonists. PCT Int. Appl. 2008, WO08051403.
50. Hatley, R. J. D.; Pinto, I. L. Preparation of halogenoalkyl xanthine derivatives as HM74A agonists. PCT Int. Appl. 2006, WO06045565.
51. Hatley, R. J. D.; Pinto, I. L. Preparation of xanthine derivatives as HM74A agonists. PCT Int. Appl. 2006, WO06045564.
52. Heer, J. P.; Smith, I. E. D. Preparation of xanthine derivatives for use in pharmaceutical compositions as selective HM74a agonists. PCT Int. Appl. 2007, WO07017265.
53. Hatley, R. J. D.; Heer, J. P.; Liddle, J.; Mason, A. M.; Pinto, I. L.; Rahman, S. S.; Smith, I. E. D. Xanthine derivatives as selective HM74A agonists and their preparation. PCT Int. Appl. 2007, WO07017262.
54. Hatley, R. J. D.; Mason, A. M.; Pinto, I. L. Preparation of xanthine derivatives as selective HM74A agonists. PCT Int. Appl. 2007, WO 07017261.
55. Metcalf, B.; Zhang, K.; Zheng, C.; Xue, C-B.; Cao, G.; Wang, A. Purinone derivatives as HM74a receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. PCT Int. Appl. 2007, WO 07150026.
56. Zheng, C.; Xue, C-B.; Cao, G.; Xia, M.; Wang, A.; Ye, H. F.; Metcalf, B. Preparation of purinone derivatives as HM74a agonists. PCT Int. Appl. 2007, WO 07150025.
57. Palani, A.; Su, J.; Xiao, D.; Huang, X.; Rao, A. U.; Chen, X.; Tang, H.; Qin, J.; Huang, Y.; Aslanian, R. G.; Mckittrick, B. Pyrano [2,3d] pyrimidines as nicotinic acid receptor agonists for the treatment of dyslipidemia and their preparation and pharmaceutical compositions. PCT Int. Appl. 2006, WO 06124490.
58. Palani, A.; Qin, J.; Xiao, D.; Huang, Y. R.; Chen, X.; Liu, Z.; Degrado, S. J.; Aslanian, R. G.; Huang, X. Preparation of heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia. U.S. Pat. Appl. Publ. 2007, US 2007173495.
59. Conte, A.; Dehmlow, H.; Grether, U.; Kratochwil, N. A.; Kuehne, H.; Narquizian, R.; Panousis, C.; Peters, J-U.; Ricklin, F.; Roever, S. Preparation of pyrido[2,3-d]pyrimidin-4-one derivatives as HM74A agonists. PCT Int. Appl. 2007, WO 07134986.
60. Brummerhop, H.; Stengelin, S.; Heuer, H.; Kilp, S.; Herling, A.; Klabunde, T.; Kadereit, D.; Urmann, M. Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome. PCT Int. Appl. 2008, WO 08086949.